Mind.Px™ is a genetic analysis test combined with preparatory Mindera Health Dermal Biomarker Patch (DBP), to provide insights on immune-related pathways involved in the pathogenesis of psoriasis. Psoriasis pathogenesis involves a complex interplay between IL-17, IL-23, and other cytokines that play crucial roles as key regulators of the chronic Inflammatory condition. By deciphering the immune pathway in an individual psoriasis lesion, Mind.Px provides a preferred disease immunopathologic pathway to support disease treatment management.
Biomarkers are extracted from a psoriatic lesion using the DBP, and from the submitted sample, data are generated using an Illumina NovaSeq 6000 system.
The Mind.Px score stratifies an individual by current immune-related pathway associated with psoriasis pathogenicity. The positive predictive value (PPV) of Mind.Px is >90%, where a positive result is defined as a patient having a minimum of a PASI75 response at 12-16 weeks after dosing.
DISCLAIMER
Mind.Px is not designed to independently diagnose, prevent, or treat any condition of disease, or to ascertain the state of an individual’s health in the absence of medical or clinical information. An individual should consult healthcare provider to make medical decision, change their health behavior or make changes to medications or dosage.
The test is intended for use as an aid for clinicians and patients considering the risks and benefits of psoriasis management and treatments.
This test was performed by Mindera Health Clinical Laboratory, 5795 Kearny Villa Rd., San Diego, CA 92123. Mindera Health Laboratory is a CLIA-certified CAP-Accredited, and HIPAA compliant laboratory (CLIA #: 05D2189599, CAP #: 8813410). A technical component of Mind.Px test was performed by Psomagen, Inc., 1330 Piccard Drive, Rockville, MD 20850. Psomagen is a CLIA-certified CAP-Accredited and HIPAA compliant laboratory (CLIA #21D2062464, CAP #: 8742212). This test has not been cleared or approved by the US Food and Drug Administration.